Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. - Wikidata - awgldk - TriplyDB

Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure.

Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure.

http://www.wikidata.org/entity/Q37318206

about

Current prospects for the fluoroquinolones as first-line tuberculosis therapy Antituberculosis therapy for 2012 and beyond Treatment of tuberculosis in a region with high drug resistance: outcomes, drug resistance amplification and re-infection Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis UniDrug-target: a computational tool to identify unique drug targets in pathogenic bacteria High proportion of heteroresistance in gyrA and gyrB in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates Investigation of the prevalence of female genital tract tuberculosis and its relation to female infertility:An observational analytical study.Rapid detection of fluoroquinolone-resistant and heteroresistant Mycobacterium tuberculosis by use of sloppy molecular beacons and dual melting-temperature codes in a real-time PCR assay Incidence of moxifloxacin resistance in clinical Mycobacterium tuberculosis isolates in Houston, Texas.A comparison of interview methods to ascertain fluoroquinolone exposure before tuberculosis diagnosis High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility.Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations.Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones.Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase.Moxifloxacin and gatifloxacin for initial therapy of tuberculosis: a meta-analysis of randomized clinical trials.Empirical use of fluoroquinolones improves the survival of critically ill patients with tuberculosis mimicking severe pneumonia.Impact of Fluoroquinolone Exposure Prior to Tuberculosis Diagnosis on Clinical Outcomes in Immunocompromised Patients Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations.Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones.Resistance to Second-Line Antituberculosis Drugs and Delay in Drug Susceptibility Testing among Multidrug-Resistant Tuberculosis Patients in Shanghai.Fluoroquinolone exposure prior to tuberculosis diagnosis is associated with an increased risk of death Microcolonies in fluoroquinolone agar proportion susceptibility testing of Mycobacterium tuberculosis: an indicator of drug resistance.Update in tuberculosis 2009.An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 2: second line drugs.Levofloxacin for the treatment of respiratory tract infections.New treatment options for multidrug-resistant tuberculosis.Introduction to propensity scores.Quinolone-containing therapies in the eradication of Helicobacter pylori Comparative economic evaluation of home-based and hospital-based palliative care for terminal cancer patients.Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.A multicenter observational study of the effectiveness of antiarrhythmic agents in ventricular arrhythmias: A propensity-score adjusted analysis.A novel resistance mutation in eccC5 of the ESX-5 secretion system confers ofloxacin resistance in Mycobacterium tuberculosis.Atrial fibrillation after lung cancer surgery: incidence, severity, and risk factors.Improved survival in patients with severe tuberculosis after exposure to fluoroquinolones.Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan.Fluoroquinolone Therapy for the Prevention of Multidrug-Resistant Tuberculosis in Contacts. A Cost-Effectiveness Analysis.Tuberculous prostate abscesses in an immunocompetent patient: A dramatic presentation of disseminated tuberculosis.Difference in toxicity reporting between patients and clinicians during systemic chemotherapy in patients with urothelial carcinoma.Effects of eating dinner alone on overweight in Japanese adolescents: a cross-sectional survey.

P2860

Q26823843-CAF09073-CF0B-43E8-9E3F-5FF68AEECDB7 Q26829101-3AC021EB-4394-405E-AE13-1C7A8C0D941B Q28476640-C29D7630-52CE-46CF-967D-111CABA0B0D0 Q28478920-F0D9C437-E3E1-4C1C-BE39-0B921D88A846 Q28481491-1859110F-ED40-4B4B-B3FC-2BAF573449EF Q33798166-11925884-D19E-4654-BF00-4065EA788EED Q34217573-A4BB0D78-8F39-4A65-8752-379EE387100A Q34741239-63F75DAD-3FBD-4287-859A-2F32648AF068 Q35139691-F669B1D9-60FA-46AC-846A-B6C2F24573F1 Q35155801-733436C2-F975-45A0-A3E8-F1A0929762BC Q35867806-2C616A32-41BF-41BB-95A5-2D02D5839E9A Q36281234-8E0BB096-E1CF-48D6-B287-5F8D3D211449 Q36288667-20F6BE92-4249-4EDD-9D3B-80C59BA70D18 Q36607348-5C3CF0B8-F5A2-42CE-9CA5-0E799AF93EB2 Q36650622-9389C09A-492B-44D9-B98D-49B619CC7608 Q36928273-E67A18AF-3069-4B83-88E5-AA23274995FF Q37023145-30FD9AB7-C0B5-4A1B-B13E-4E0E5BBE8921 Q37177278-5D9C9065-291B-45BF-BA0C-CAE2508C1ABB Q37191156-3DA70CD7-1532-48BA-B4CE-09B1D0CE9660 Q37249837-FFFD1063-EC42-4970-AD57-7674FCD45185 Q37694565-09E5337E-1669-4381-A7CD-90A936F34394 Q37694594-22F49131-683B-43F4-8C00-81CE165482A4 Q37704062-773EC338-A252-43C4-9069-F09B8C04D299 Q37799461-DC086F6F-F6AF-4AC6-8EDD-B0BA1012F392 Q37810481-C76CA47B-B16A-4D69-A8FC-CA3A0C8B3293 Q38010784-B44392AD-3630-4D89-B084-21F4AE0794CC Q38024041-BDCC5328-7A8A-4922-BF9A-D9C9BCD42318 Q38217008-D07E901F-2F5B-40AB-B129-0D1F46010367 Q38253054-2A2C86B4-F1A3-4937-A5CE-20E37297BCA6 Q38970364-DCE4AB7E-BF7A-44E3-B393-52E4D8C03AD8 Q38979626-3F75647D-5482-4E1A-A312-32D2D59F6F1F Q39646654-9880162F-FA0A-4C32-9BB7-936746A4FFBB Q40645861-D73077E0-2858-475A-8E1B-115034702316 Q40665336-643E473C-A709-4973-8045-B2E0A1E578FA Q40688793-8B97502C-8122-4A3E-837F-630470AEEC16 Q40957363-030833EF-BC1C-43B7-82B4-9FA19CF16605 Q41009954-F99FAA27-FAB1-45A2-AE55-40D3312CBDC7 Q41038046-209B8ED3-8251-4374-9242-0A1CE32F274E Q47426076-EFBEB9A2-76E8-4708-9C9C-CCDEE0D2976A Q48503044-FFCEB93B-B52D-41F6-9CBE-F3AAC0683E5D

P2860

Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure.

http://www.wikidata.org/entity/Q37318206

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 29 May 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Fluoroquinolone resistance in ...... g of fluoroquinolone exposure.

@en

Fluoroquinolone resistance in ...... g of fluoroquinolone exposure.

@nl

type

label

Fluoroquinolone resistance in ...... g of fluoroquinolone exposure.

@en

Fluoroquinolone resistance in ...... g of fluoroquinolone exposure.

@nl

prefLabel

Fluoroquinolone resistance in ...... g of fluoroquinolone exposure.

@en

Fluoroquinolone resistance in ...... g of fluoroquinolone exposure.

@nl

P1433

Q37318206-053A0716-8450-4AB3-969F-77DF5C0E920B

P1476

Q37318206-DA189149-2D56-42E9-8FD2-21C141C2BFAD

P2093

Q37318206-2049728D-C08C-4705-9BE4-AB353B757965

Q37318206-20B97FB9-42BA-4A86-A045-7F53BBC8B971

Q37318206-51A8A6EC-0382-48A6-A6CE-62FF42CB1C2D

Q37318206-53933700-B2F3-46E4-9FD1-CAFAC1E71ADE

Q37318206-76A174DA-E46A-4B02-AFAE-86939012D935

Q37318206-7B224341-AE36-46A1-8629-6B56191EFEB8

Q37318206-A2616B1E-0374-4DFF-A7BD-0267DA26FC2F

Q37318206-A2E5BA4D-B986-4D1F-AFE0-542D1F86BE8F

Q37318206-EC3F37E1-CD92-46A0-AABE-06D8EBEDBE03

Q37318206-ED082C06-CC97-44A9-80CA-914EADE2AAF4

P2860

Q37318206-0605CA78-C526-44ED-9DDD-CEEFB5AA3421

Q37318206-18EF10AA-F72E-47D1-8845-178DA3223D43

Q37318206-19217F8E-FDE6-4FC9-9CF3-82893ED8568C

Q37318206-2D59DB6B-FC09-43AD-BBB7-9988D71237EE

Q37318206-45C2E87E-B544-48B7-85B4-923C1162CCA2

Q37318206-4CF9E5A2-CAEF-43DF-BAB3-687E008E1CE9

Q37318206-52E4C225-592E-4B0A-AE42-C8B3F7D003FF

Q37318206-67D25F95-5CB5-4494-A3C9-C52221D6F6B2

Q37318206-8365F9D7-7431-4789-882B-648A59068E72

Q37318206-A0B55D69-A5E4-40C3-8E81-0496CD467B9A

P304

Q37318206-F88ABA60-B9F6-4D09-9A6E-52BCDD312241

P31

Q37318206-C5D58FA1-C111-44C9-8A19-651476374058

P356

Q37318206-28262473-950A-4F82-9788-F066654ABAFE

P407

Q37318206-23F009F5-E8F7-4E75-9C98-4892805A3E57

P433

Q37318206-34EC6A36-A1F3-4DCC-8D82-B1E37E629ECE

P478

Q37318206-CB07B4D9-03D4-4E58-A661-8795B7D945B0

P50

Q37318206-650087CF-733F-4EC1-A8D3-01F93C832CC0

P577

Q37318206-4CA6E5BD-2902-4489-8D00-B832C56F3F44

P698

Q37318206-31AF0FD3-6246-4622-A763-E91DF90DAFBD

P921

Q37318206-2F5E2064-49CA-45BB-AA1C-5EC5CC23753F

Q37318206-679DC2FF-B39E-4815-AF49-7300E2A975A3

P932

Q37318206-A7C549B6-C453-45CF-BDB3-FEC3A3CE62CC

P356

RCCM.200901-0146OC

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Fluoroquinolone resistance in ...... g of fluoroquinolone exposure.

@en

P2093

Amondrea Blackman

http://www.w3.org/2001/XMLSchema#string

Ayumi Shintani

http://www.w3.org/2001/XMLSchema#string

Carolyn May

http://www.w3.org/2001/XMLSchema#string

Ed Mitchel

http://www.w3.org/2001/XMLSchema#string

Fernanda Maruri

http://www.w3.org/2001/XMLSchema#string

Jon Warkentin

http://www.w3.org/2001/XMLSchema#string

Marie Griffin

http://www.w3.org/2001/XMLSchema#string

Nancy Hooper

http://www.w3.org/2001/XMLSchema#string

Rose A Devasia

http://www.w3.org/2001/XMLSchema#string

Teresa Smith

http://www.w3.org/2001/XMLSchema#string

P2860

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

Evaluation of a two-step approach for large-scale, prospective genotyping of Mycobacterium tuberculosis isolates in the United States.

A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.

Fluoroquinolone prescribing in the United States: 1995 to 2002.

In-vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis.

Impact of short-term exposure to fluoroquinolones on ofloxacin resistance in HIV-negative patients with tuberculosis.

In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis.

Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada.

The rapid development of fluoroquinolone resistance in M. tuberculosis.

P304

365-370

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.200901-0146OC

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

180

http://www.w3.org/2001/XMLSchema#string

P50

Tebeb Gebretsadik

P577

2009-05-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19483111

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

Mycobacterium tuberculosis

P932

2731810

http://www.w3.org/2001/XMLSchema#string